Standout Papers

Spironolactone versus ... 1980 2026 1995 2010 707
  1. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial (2015)
    Bryan Williams, Thomas M. MacDonald et al. The Lancet
  2. Regulation of the immune response by prostaglandins (1980)
    James S. Goodwin, David R. Webb Clinical Immunology and Immunopathology
  3. Type 2 diabetes (2022)
    Ehtasham Ahmad, Soo Lim et al. The Lancet
  4. Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective (2015)
    Francesco Zaccardi, David R. Webb et al. Postgraduate Medical Journal
  5. Efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes mellitus: systematic review and network meta‐analysis (2016)
    Francesco Zaccardi, David R. Webb et al. Diabetes Obesity and Metabolism

Immediate Impact

17 by Nobel laureates 16 from Science/Nature 60 standout
Sub-graph 1 of 21

Citing Papers

New perspectives in diabetic neuropathy
2023 Standout
Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension
2022 Standout

Works of David R. Webb being referenced

Type 2 diabetes
2022 Standout
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial
2015 Standout

Author Peers

Author Last Decade Papers Cites
David R. Webb 3590 1179 2102 1545 319 10.5k
Qiang Li 3146 833 1989 1128 428 11.7k
Merlin C. Thomas 5914 1167 4148 3397 344 18.2k
Yuan Zhang 1225 883 1891 1896 534 10.8k
Jianping Weng 5168 360 3627 1296 320 11.9k
Timothy M. E. Davis 6180 1064 2736 2306 593 20.9k
Li Chen 3496 570 5677 1576 508 15.3k
Janet Wittes 2414 1794 2480 4194 159 14.8k
Junichi Sasaki 2711 1060 2547 2688 537 13.4k
Cheng‐Chieh Lin 1616 1070 2817 930 558 12.0k
Ulrich Keller 2866 933 3232 895 360 13.7k

All Works

Loading papers...

Rankless by CCL
2026